RxDoctor Payments Data

Jessica McKee, DO

Internal Medicine · Wilson, NCNPI 1083637391

Payments from drug & device makers

$139in general payments, 2019–2025

Across 11 payments — averaging $12.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$34
  • AstraZeneca$27
  • Novo Nordisk$15
  • GSK$14
  • Amgen$13
  • Merck$13
  • plus $23 from 2 others

What the payments were for

  • Food & beverage$139100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$139 in reported general payments places this provider in the 45th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$137,815
Medicare patients
340
Services billed
1,547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide83$105,997
FarxigaDapagliflozin Propanediol86$80,168
RybelsusSemaglutide45$78,121
JardianceEmpagliflozin82$69,364
EliquisApixaban20$26,376
MyrbetriqMirabegron25$20,831
XareltoRivaroxaban22$20,047
JanuviaSitagliptin Phosphate35$19,316
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$17,133
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro23$6,675
Irbesartan335$6,274
Humalog Kwikpen U-100Insulin Lispro14$5,711
Losartan Potassium475$5,179
Rosuvastatin Calcium367$4,081
Levothyroxine Sodium411$3,854

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$15$184,118128 claims
AstraZenecaFarxiga$27$80,16886 claims
Boehringer IngelheimJardiance$34$69,36482 claims
PfizerEliquis$11$26,37620 claims
MerckJanuvia$13$19,31635 claims
GSKTrelegy Ellipta$14$17,13319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Wilson

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →